Pivotal Odronextamab (CD20xCD3) Section 2 Knowledge in Sufferers with Relapsed/Refractory Diffuse Huge B-cell Lymphoma Debut at ASH
49% goal reaction charge (ORR) in closely pre-treated
Stay Safe and Healthy
49% goal reaction charge (ORR) in closely pre-treated